Cargando…

Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response

Low-dose thalidomide and prednisone alone or combined are effective therapies in some persons with primary myelofibrosis (PMF) and anemia with or with RBC transfusion dependence. Danazol is also effective in some persons with PMF and anemia. Responses to these drugs are typically incomplete and not...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Xueping, Xu, Zefeng, Li, Bing, Qin, Tiejun, Zhang, Peihong, Zhang, Hongli, Fang, Liwei, Pan, Lijuan, Hu, Naibo, Qu, Shiqiang, Zhang, Yue, Huang, Gang, Peter Gale, Robert, Xiao, Zhijian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802625/ https://www.ncbi.nlm.nih.gov/pubmed/29335406 http://dx.doi.org/10.1038/s41408-017-0029-4

Ejemplares similares

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
por: Li, Bing, et al.
Publicado: (2017)

Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R
por: Li, Bing, et al.
Publicado: (2016)

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia
por: Cui, Yajuan, et al.
Publicado: (2015)

A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes
por: Feng, Gege, et al.
Publicado: (2016)

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression
por: Yan, Xin, et al.
Publicado: (2023)

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
por: Hu, Naibo, et al.
Publicado: (2021)

Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromes
por: Wang, Jingya, et al.
Publicado: (2016)

RBC distribution width predicts thrombosis risk in polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms
por: Zhang, Yudi, et al.
Publicado: (2022)

Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre
por: Huang, Huijun, et al.
Publicado: (2020)

A case of granuloma faciale successfully treated with oral prednisone, tranilast and thalidomide
por: Yuan, Chunyu, et al.
Publicado: (2018)

Successful treatment of an adult with Kasabach-Merritt syndrome using thalidomide, vincristine, and prednisone
por: Huang, Yue-Hua, et al.
Publicado: (2019)

Case of cryptic TNIP1::PDGFRB rearrangement presenting with myelodysplastic syndrome achieved hematologic and cytogenetic remission with low-dose imatinib plus decitabine therapy
por: Qu, Shiqiang, et al.
Publicado: (2023)

Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial
por: Wang, Yawen, et al.
Publicado: (2022)

ASXL2 mutated myelodysplastic syndrome in a novel germline G6b variant
por: Qu, Shiqiang, et al.
Publicado: (2022)

PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN)
por: Masarova, Lucia, et al.
Publicado: (2023)

Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China
por: Liu, Xiangli, et al.
Publicado: (2019)

CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia
por: Cui, Yajuan, et al.
Publicado: (2014)

Danazol in Refractory Autoimmune Hemolytic Anemia or Immune Thrombocytopenia: A Case Series Report and Literature Review
por: Huang, Hsu-En, et al.
Publicado: (2022)

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients
por: Sun, Yuanyuan, et al.
Publicado: (2020)

Long-term prophylaxis of hereditary angioedema with danazol
por: Xu, Yingyang, et al.
Publicado: (2022)

Danazol: An Effective Option in Acquired Amegakaryocytic Thrombocytopaenic Purpura
por: Mulroy, E., et al.
Publicado: (2015)

P1133: CHIDAMIDE PLUS PREDNISONE, CYCLOPHOSPHAMIDE, AND THALIDOMIDE (CPCT) FOR RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER PHASE II TRIAL
por: Liang, Jinhua, et al.
Publicado: (2023)

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder
por: Huang, Huijun, et al.
Publicado: (2021)

Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy
por: Guo, Yaling, et al.
Publicado: (2020)

Danazol: An Effective and Underutilised Treatment Option in Diamond-Blackfan Anaemia
por: Chai, Kern Y., et al.
Publicado: (2019)

Cyclical Thrombocytopenia Synchronized With the Patient’s Menstrual Cycle Treated With Danazol
por: Menakuru, Sasmith R., et al.
Publicado: (2022)

No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis
por: Hoffman, Thijs W., et al.
Publicado: (2023)

P1050: THROMBOCYTOPENIC MYELOFIBROSIS (MF) PATIENTS PREVIOUSLY TREATED WITH A JAK INHIBITOR IN A PHASE 3 RANDOMIZED STUDY OF MOMELOTINIB (MMB) VERSUS DANAZOL (DAN) [MOMENTUM]
por: Vannucchi, A., et al.
Publicado: (2022)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Emerging Treatment Options for Myelofibrosis: Focus on Anemia
por: Sastow, Dahniel, et al.
Publicado: (2023)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

Romiplostim plus danazol as salvage treatment for eltrombopag refractory immune thrombocytopenia: a retrospective pilot study
por: Nam, Chang Hyun, et al.
Publicado: (2021)

Conventional interferon-a 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: a retrospective study based on 286 patients from a single center
por: Liu, Dan, et al.
Publicado: (2022)

The effect of long-term danazol treatment on haematological parameters in hereditary angioedema
por: Kőhalmi, Kinga Viktória, et al.
Publicado: (2016)

Enhanced bioavailability of danazol nanosuspensions by wet milling and high-pressure homogenization
por: Kanthamneni, Naveen, et al.
Publicado: (2016)

Successful treatment of telomeropathy‐related interstitial lung disease with immunosuppression and danazol
por: Chambers, Daniel C., et al.
Publicado: (2020)

Danazol as a Treatment for Uterine Arteriovenous Malformation: A Case Report
por: Tak, Hyunjin, et al.
Publicado: (2023)

Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
por: Yang, Zhenyu, et al.
Publicado: (2021)

A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma
por: Chang, Hye Jung, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4il58c9u7oh22u3vtsvak9bq7r